Amicus Therapeutics Inc. (FOLD)

Name: Amicus Therapeutics Inc. (FOLD) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Amicus Therapeutics Inc. (FOLD)

Stock Card

$14.49

$0.00 (0.00%)

As on 27-Apr-2026 09:30EDT

Market cap

$4,550 Mln

Revenue (TTM)

$634 Mln

P/E Ratio

P/B Ratio

16.6

Div. Yield

0 %

Amicus Therapeutics (FOLD) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 14.49 High: 14.49

52 Week Range

Low: 5.51 High: 14.50

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

87.3
Debt to Equity

1.8
Book Value

$0.9
EPS

$-0.1
Face value

--
Shares outstanding

314,000,712

10 Years Aggregate

CFO

$-1,739.65 Mln

EBITDA

$-1,894.10 Mln

Net Profit

$-2,305.94 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Amicus Therapeutics (FOLD)	1.8	0.4	1.4	97.1	7.8	7.4	6.2
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Apr-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Amicus Therapeutics (FOLD)	51.2	-33.4	16.2	5.7	-50.0	137.1	1.7
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Amicus Therapeutics (FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of... Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc. Read more

CEO, President & Director

Mr. Bradley L. Campbell M.B.A.
CEO, President & Director

Mr. Bradley L. Campbell M.B.A.
Headquarters

Princeton, NJ
Website

https://amicusrx.com

FAQs for Amicus Therapeutics (FOLD)

What is the current share price of Amicus Therapeutics Inc (FOLD) Today?

The share price of Amicus Therapeutics Inc (FOLD) is $14.49 (NASDAQ) as of 27-Apr-2026 09:30 EDT. Amicus Therapeutics Inc (FOLD) has given a return of 7.82% in the last 3 years.

What is the current PB & PE ratio of Amicus Therapeutics Inc (FOLD)?

Since, TTM earnings of Amicus Therapeutics Inc (FOLD) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-165.12	16.32
2024	-50.21	14.52
2023	-27.48	26.01
2022	-14.51	27.89
2021	-12.86	10.48

What is the 52 Week High and Low of Amicus Therapeutics Inc (FOLD)?

The 52-week high and low of Amicus Therapeutics Inc (FOLD) are Rs 14.50 and Rs 5.51 as of 01-Sep-2026.

What is the market cap of Amicus Therapeutics Inc (FOLD)?

Amicus Therapeutics Inc (FOLD) has a market capitalisation of $ 4,550 Mln as on 27-Apr-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Amicus Therapeutics Inc (FOLD)?

Before investing in Amicus Therapeutics Inc (FOLD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.